{"organizations": [], "uuid": "e57dc6c80d7fa7db560b3e9460dd93baadec8031", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/personal-finance/analyst-research", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "https://www.reuters.com/article/brief-pulse-biosciences-announces-positi/brief-pulse-biosciences-announces-positive-results-from-its-first-study-evaluating-a-clinical-target-at-major-scientific-meeting-idUSFWN1RP12O", "country": "US", "domain_rank": 408, "title": "Pulse Biosciences Announces Positive Results From Its First Study Evaluating A Clinical Target At Major Scientific Meeting", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.843, "site_type": "news", "published": "2018-04-13T05:24:00.000+03:00", "replies_count": 0, "uuid": "e57dc6c80d7fa7db560b3e9460dd93baadec8031"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pulse-biosciences-announces-positi/brief-pulse-biosciences-announces-positive-results-from-its-first-study-evaluating-a-clinical-target-at-major-scientific-meeting-idUSFWN1RP12O", "ord_in_thread": 0, "title": "Pulse Biosciences Announces Positive Results From Its First Study Evaluating A Clinical Target At Major Scientific Meeting", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "major scientific meeting  pulse biosciences inc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12 (Reuters) - Pulse Biosciences Inc:\n* PULSE BIOSCIENCES ANNOUNCES POSITIVE RESULTS FROM ITS FIRST STUDY EVALUATING A CLINICAL TARGET AT MAJOR SCIENTIFIC MEETING\n* AN INDEPENDENT, BLINDED PHOTOGRAPHIC REVIEW OF LESION IMAGES SCORED 71% OF LESIONS AS CLEAR OR MOSTLY CLEAR IN TRIAL\n* PATIENTS RATED 78% OF LESION OUTCOMES AS SATISFIED OR MOSTLY SATISFIED, CLOSELY MIRRORING INVESTIGATOR RATINGS Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-13T05:24:00.000+03:00", "crawled": "2018-04-13T00:27:09.012+03:00", "highlightTitle": ""}